Content Type: Commentary & Opinion

Certification Marks for Supporting Generic Drug Quality

March 6, 2026

Sotorasib’s Accelerated Approval: Wrong Dose and Indication

March 6, 2026

Leveraging Old Hepatitis C Therapies

March 6, 2026

The Role of Importation in Remediating U.S. Generic Drug Shortages

March 6, 2026

Op-Ed: How to Protect HHS, FDA, NIH, and Other Health Agencies From Political Interference

March 6, 2026

AI Devices in Neurology-Moving From Diagnosis to Prognosis

March 6, 2026

Out of Pocket Getting Out of Hand—Reducing the Financial Toxicity of Rapidly Approved Drugs

March 6, 2026

The Moral Injury of Inhaler Prescribing

March 6, 2026

Using Trademarks to Ensure Completion of Postapproval Trials

March 6, 2026

Op-Ed: Lessons from Humira on How to Tackle Unjust Extensions of Drug Monopolies with Policy

March 6, 2026

Revising EU Pharmaceutical Legislation: Will It Foster Drug Repurposing?

March 6, 2026

Medicare’s First Round of Drug-Price Negotiation—Measuring Success

March 6, 2026